


### **EUPATI WEBINAR**

# Community Advisory Boards Quick Introduction




Rob Camp 28 June 2018

**EURORDIS.ORG** 



Clip slide

#### Patient involvement in practice within the R&D life cycle



## A Community Advisory Board is




- A group of patients who offer their expertise to public or private sponsors of clinical research
  - Overall programme development
  - ➤ A single clinical trial
  - Other aspects beyond the research programme
- The same group of patients advises several sponsors in their field
  - Avoids selection of patients' representatives by the sponsor
- Agenda and secretariat driven by the patients



# Same disease area, different sponsors






### SCOPE













# Trial protocol

All aspects, not just informed consent

## Strategy trials

Collaboration with competitors

Compassion ate use programme

Pipeline drug development portfolio and plan

# Reasonable pricing

World-wide Access
Patent availability to
generics companies

 Also Community Relations (DSMBs, Investigator Meetings), marketing practices and publicity...



### **Value**

- Shorten the development time
- More patient-friendly PROMs
- Faster recruitment/less drop-outs
- Registries
- Disease environment
  - ➤ Real-life experience + social responsibility
- Higher quality results
  - Faster approval + market access.





#### Forward ho!

- October European Round Table of Companies meeting Barcelona - the value of listening to patients early
- CFE, Duchenne, TSC
- <u>rob.camp@eurordis.org</u>, francois.houyez@eurordis.org



